Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of the NEXLETOL™ (bempedoic acid) Tablet and Phase 2 Study Results of the NEXLIZET™ (bempedoic acid and e...
Esperion Therapeutics, Inc. (ESPR)
Last esperion therapeutics, inc. earnings: 2/27 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.esperion.com
Company Research
Source: GlobeNewswire
ANN ARBOR, Mich., March 23, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that two pooled analyses from four Phase 3 clinical trials of NEXLETOL and results from the Phase 2 (1002-058) study of NEXLIZET will be presented at the American College of Cardiology’s 69th Scientific Session Together with World Congress of Cardiology (ACC.20/WCC) on March 28th – 30th 2020. Esperion completed its global, pivotal, Phase 3 LDL-C lowering development program and announced positive cumulative results in October 2018. The program evaluated the safety, tolerability and LDL-C lowering efficacy of NEXLETOL and NEXLIZET in patients with hypercholesterolemia who either have atherosclerotic cardiovascular disease (ASCVD) or are at high risk of ASCVD, and who continue to have elevated levels of LDL-C despite the use of maximally-tolerated statins and ezetimibe, leaving them at high risk for cardiovascular events. The program included over 4,000 patients across five studies, four for N
Show less
Read more
Impact Snapshot
Event Time:
ESPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ESPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ESPR alerts
High impacting Esperion Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ESPR
News
- Esperion Therapeutics, Inc. (NASDAQ: ESPR) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "neutral" rating and a $4.00 price target on the stock.MarketBeat
- Esperion Strengthens Balance Sheet with Closing of Significant Refinancing TransactionsGlobeNewswire
- Esperion Therapeutics, Inc. (NASDAQ: ESPR) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $8.00 price target on the stock.MarketBeat
- Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $6.00 price target on the stock.MarketBeat
- Esperion Announces $210 Million Convertible Debt FinancingGlobeNewswire
ESPR
Earnings
- 11/7/24 - Miss
ESPR
Sec Filings
- 12/18/24 - Form 4
- 12/18/24 - Form 4
- 12/18/24 - Form 4
- ESPR's page on the SEC website